Literature DB >> 34208082

The Effects of Food on Cannabidiol Bioaccessibility.

Khadijeh Mozaffari1, Stephanie Willette2, Ben F Lucker2, Sarah E Kovar2, Francisco Omar Holguin1, Ivette Guzman1.   

Abstract

Cannabidiol (CBD) is a hydrophobic non-psychoactive compound with therapeutic characteristics. Animal and human studies have shown its poor oral bioavailability in vivo, and the impact of consuming lipid-soluble CBD with and without food on gut bioaccessibility has not been explored. The purpose of this research was to study the bioaccessibility of CBD after a three-phase upper digestion experiment with and without food, and to test lipase activity with different substrate concentrations. Our results showed that lipase enzyme activity and fatty acid absorption increased in the presence of bile salts, which may also contribute to an increase in CBD bioaccessibility. The food matrix used was a mixture of olive oil and baby food. Overall, the fed-state digestion revealed significantly higher micellarization efficiency for CBD (14.15 ± 0.6% for 10 mg and 22.67 ± 2.1% for 100 mg CBD ingested) than the fasted state digestion of CBD (0.65 ± 0.7% for 10 mg and 0.14 ± 0.1% for 100 mg CBD ingested). The increase in bioaccessibility of CBD with food could be explained by the fact that micelle formation from hydrolyzed lipids aid in bioaccessibility of hydrophobic molecules. In conclusion, the bioaccessibility of CBD depends on the food matrix and the presence of lipase and bile salts.

Entities:  

Keywords:  CBD; UPLC-MS; cannabis; fasted digestion; fed digestion; hemp; in vitro digestion; metabolites

Year:  2021        PMID: 34208082     DOI: 10.3390/molecules26123573

Source DB:  PubMed          Journal:  Molecules        ISSN: 1420-3049            Impact factor:   4.411


  3 in total

1.  Biophysical Studies and In Vitro Effects of Tumor Cell Lines of Cannabidiol and Its Cyclodextrin Inclusion Complexes.

Authors:  Kyriaki Hatziagapiou; Kostas Bethanis; Eleni Koniari; Elias Christoforides; Olti Nikola; Athena Andreou; Aimilia Mantzou; George P Chrousos; Christina Kanaka-Gantenbein; George I Lambrou
Journal:  Pharmaceutics       Date:  2022-03-26       Impact factor: 6.525

Review 2.  Tetrahydrocannabinol and cannabidiol medicines for chronic pain and mental health conditions.

Authors:  Jeremy D Henson; Luis Vitetta; Sean Hall
Journal:  Inflammopharmacology       Date:  2022-07-07       Impact factor: 5.093

Review 3.  Enhancing Endocannabinoid Control of Stress with Cannabidiol.

Authors:  Jeremy D Henson; Luis Vitetta; Michelle Quezada; Sean Hall
Journal:  J Clin Med       Date:  2021-12-14       Impact factor: 4.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.